3:26 PM
 | 
Feb 22, 2019
 |  BC Extra  |  Company News

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

Based on the number of years of life it adds, spinal muscular atrophy therapy Zolgensma onasemnogene abeparvovec (AVXS-101) would be cost effective if priced under $1.5 million per year, according to an evidence report released Friday from the Institute for Clinical and Economic Review (ICER). The SMA candidate from Novartis AG (NYSE:NVS; SIX:NOVN) is under FDA review with a decision expected this half.

While ICER typically evaluates a drug's cost effectiveness based on quality-associated life years (QALYs), ICER President Steven Pearson told BioCentury the institute recently decided to make life years gained (LYGs) -- or a similar metric, equal value of life years gained (evLYG) -- a more prominent part of its executive summary and value-based pricing calculations to provide policymakers with a broader view...

Read the full 606 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >